NCT05503407已完成不适用
Baseline V-RESOLVE Score Guided Versus Angiography Guided Stent Implantation in Coronary Bifurcation Lesions (CIT-RESOLVE II)
China National Center for Cardiovascular Diseases1 个研究点 分布在 1 个国家目标入组 1,104 人开始时间: 2017年1月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 1,104
- 试验地点
- 1
- 主要终点
- side branch occlusion after main vessel stenting
研究概览
简要总结
The purpose of this study is to investigate whether baseline V-RESOLVE score guided intervention is associated with significant reduction of side branch occlusion rates compared to angiography guided intervention in patients with coronary bifurcation lesions.
详细描述
A number of 1104 patients scheduled for elective percutaneous coronary intervention (PCI) with native coronary bifurcation lesions suitable for stent implantation are included in the present study. This study will be conducted in two stages with 552 patients each. In the first stage, all patients receive angiography-guided PCI. In the second stage, all patients receive PCI under the guidance of baseline V-RESOLVE score.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinical Inclusion Criteria:
- •Subject must be male or nonpregnant female ≥18 years of age and ≤75 years of age;
- •Subject has symptomatic coronary artery disease with objective evidence of ischemia or silent ischemia;
- •Subject is eligible for PCI;
- •Subject (or legal guardian) understands the trial requirements and the treatment procedures and provides written informed consent before any trial-specific tests or procedures are performed;
- •Subject is willing to comply with all protocol-required follow-up evaluation.
- •Angiographic Inclusion Criteria:
- •Subjects have coronary bifurcation lesions requiring PCI with stent implantation according to clinical guidelines and/or the operator's judgement;
- •Visually estimated reference vessel diameter (RVD) of target main vessel ≥2.5 mm and ≤4.0 mm;
- •Visually estimated RVD of target side branch ≥ 2.0mm;
- •Coronary anatomy is likely to allow delivery of a study device to the target lesion(s);
排除标准
- •Clinical Exclusion Criteria:
- •Subject has a known allergy to contrast (that cannot be adequately pre-medicated) and/or the trial stent system or protocol-required concomitant medications (e.g., stent alloy, stainless steel, sirolimus, everolimus or structurally related compounds, polymer or individual components, all P2Y12 inhibitors, or aspirin);
- •Planned surgery within 6 months after the index procedure;
- •Subject has one of the following (as assessed prior to the index procedure):
- •Other serious medical illness (e.g., cancer, congestive heart failure) with estimated life expectancy of less than 12 months;
- •Current problems with substance abuse (e.g., alcohol, cocaine, heroin, etc.);
- •Planned procedure that may cause non-compliance with the protocol or confound data interpretation;
- •Subject has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions;
- •Subject is participating in another investigational drug or device clinical trial that has not reached its primary endpoint;
- •Subject intends to participate in another investigational drug or device clinical trial within 12 months after the index procedure;
- •Subject with known intention to procreate within 12 months after the index procedure (women of child-bearing potential who are sexually active must agree to use a reliable method of contraception from the time of screening through 12 months after the index procedure);
- •Subject is a woman who is pregnant or nursing (a pregnancy test must be performed within 7 days prior to the index procedure in women of child-bearing potential);
- •Subject with left ventricular ejection fraction < 35%;
- •Subject has preoperative renal dysfunction: serum creatinine>2.0mg/dl (176.82umol/L).
- •Angiographic Exclusion Criteria:
- •Left main lesions;
- •In case of acute myocardial infarction of which the culprit vessel located at the left anterior descending (LAD) artery, the bifurcation lesion (LAD/diagonal branch [RVD>2.5mm]) which is proximal to occluded LAD segment should be excluded.
结局指标
主要结局
side branch occlusion after main vessel stenting
时间窗: Immediately after the main vessel
The primary endpoint is side branch occlusion, which is defined as any decrease in TIMI flow grade or absence of flow in side branch after main vessel stent well opposed.
次要结局
- Major adverse cardiac events (MACE)(12-month follow-up)
- The elevation of biomarkers of periprocedural myocardial injury [Creatine Kinase-Myocardial Band (CK-MB) and Troponin I].(48h after Percutaneous Coronary Intervention (PCI))
研究者
Kefei Dou, MD
Professor
China National Center for Cardiovascular Diseases
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Assessment of veins of the platelet donors using a scoring tool and studying the outcomes related to each vein scored.CTRI/2021/01/030452Malabar Cancer Centre200
Unknown
不适用
Ultrasound in Assessing Antiangiogenic Treatment in Patients With Advanced Kidney CancerKidney CancerMetastatic CancerNCT01105364National Cancer Institute, France50
终止
不适用
Assessment of Coronary Artery Lesion Using Optical Coherence Tomography Versus IntraVascular Ultrasound for BiorEsorbable Vascular Scaffold ImplantationCoronary Artery DiseaseNCT02814578Young-Hak Kim, MD, PhD9
已完成
不适用
MULTivessel Immediate Versus STAged RevaScularization in Acute Myocardial Infarction -The MULTISTARS AMI TrialST-elevation Myocardial InfarctionMultivessel Coronary DiseaseNCT03135275University of Zurich840
已完成
不适用
Efficacy of PPV/SVV ratio to assess dynamic arterial elastance in patients receiving differential lung ventilatioJPRN-UMIN000011289Osaka City University Graduate School of Medicine50